EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genetic Predisposition to MASLD: Potential for Therapeutic Management

Fani Karapanagiotidi, Chrysoula Boutari iD, Emmanouil Sinakos iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27041933 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Fani Karapanagiotidi und 2 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54642 Thessal…. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is now the most common liver disease worldwide, with a continuously increasing prevalence. The mechanisms involved in its pathophysiology are numerous and may include metabolic, environmental, and genetic factors. Genome-wide association studies have identified key genetic variants, most notably in PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13. This mini review discusses the mechanisms through which these variants contribute to the disease pathogenesis, an area that remains a rapidly evolving field of research. Beyond improving our understanding of MASLD, the identification of these variants may also aid in the development of targeted pharmacological approaches. We first summarize the major genetic variants associated with MASLD and then present findings from studies exploring how these variants may influence the efficacy of emerging pharmacotherapies. Finally, we examine the therapeutic agents in the field of precision medicine that are currently being tested in clinical trials. These therapeutic opportunities are a promising approach that may provide individualized solutions for this chronic liver disorder that affects a wide range of the population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseFatty LiverNon-alcoholic Fatty Liver DiseaseHumansGenome-Wide Association StudyAcyltransferasesMembrane ProteinsPhospholipases A2, Calcium-Independent17-Hydroxysteroid DehydrogenasesLipaseAnimalsAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

GCKRHSD17B13MBOAT7PNPLA3TM6SF2metabolic dysfunction-associated steatotic liver disease

Substanzen

AcyltransferasesMembrane ProteinsPhospholipases A2, Calcium-Independent17-Hydroxysteroid DehydrogenasesPNPLA3 protein, humanLipaseHSD17B13 protein, humanAdaptor Proteins, Signal TransducingMBOAT7 protein, humanTM6SF2 protein, human

Autor:innen und Institutionen

  • 4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54642 Thessaloniki, Greece.

ORCID-Profile: Chrysoula Boutari, Emmanouil Sinakos

Zitieren

APA

Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026). Genetic Predisposition to MASLD: Potential for Therapeutic Management. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041933

Vancouver

Karapanagiotidi F, Boutari C, Sinakos E. Genetic Predisposition to MASLD: Potential for Therapeutic Management. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041933

BibTeX
@article{Karapanagiotidi2026,
  author = {Karapanagiotidi, Fani and Boutari, Chrysoula and Sinakos, Emmanouil},
  title = {Genetic Predisposition to MASLD: Potential for Therapeutic Management},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27041933}
}
Kostenlos starten →